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Figure 1. Surface ECG and intracardiac electrograms are 
depicted on the left panel and electroanatomical mapping 
on the right panel (see text for discussion) 
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The TCT Annual Conference will be held in San 
Francisco 7-11/11/2011  
 
The AHA Annual Scientific Sessions are scheduled for 
12-16/11/2011 in Orlando 
 
The next ACC Annual Meeting is slated for 24-
27/3/2012 in Chicago 
 
The Athens Cardiology Update 2012 is slated for April 
5-7, 2012 
 
The HRS 33rd Annual Meeting will be held in Boston, 9-
12/5/2012 
 
The next ESC Annual Congress will be held in Munich, 
25-29/8/2012 
 
Incidence and Predictors of ICD Therapy in Patients 
With Arrhythmogenic Right Ventricular Dysplasia/ 
Cardiomyopathy (ARVC) Undergoing ICD 
Implantation for Primary Prevention 
Eighty-four patients with definite or probable ARVC 
underwent ICD implantation for primary prevention. 
After a follow-up of 4.7 ± 3.4 years, appropriate ICD 
therapy was delivered in 40 patients (48%). Predictors of 
such an intervention were proband status (p < 0.001), 
inducibility at electrophysiologic study (p = 0.005), 
presence of nonsustained ventricular tachycardia (p < 
0.001), and Holter premature ventricular complex count 
>1,000/24 h (p = 0.024). In multivariate analysis, 
inducibility at electrophysiologic study and nonsustained 
ventricular tachycardia remained significant predictors. 
The number of these risk factors correlates with the 
incidence of ICD activation with the 5-year survival free 
of appropriate ICD therapy for patients with 1, 2, 3, and 4 
risk factors being 100%, 83%, 21%, and 15%, 
respectively (Bhonsale A et al, J Am Coll Cardiol 2011; 
58:1485-1496).  
 
Exclusion of the Left Atrial Appendage with a Novel 
Device: Early Results of a Multicenter Trial 
Seventy patients with atrial fibrillation or a CHADS2 
score greater than 2 undergoing elective cardiac surgery 
were eligible for concomitant AtriClip device (35, 40, 45, 
and 50 mm) insertion. Safety was assessed at 30 days, 
and efficacy of left atrial appendage exclusion was 
assessed at operation (by transesophageal 
echocardiography) and at 3-month follow-up (by 
computed tomography angiography or transesophageal 
echocardiography). Intraprocedural success reached 
95.7% (67 of 70 patients). Although significant adverse 
events occurred in 34 of 70 patients (48.6%), none was 
related to the device and there was no perioperative 
mortality. At 3-month follow-up, 98.4% of the patients 
had successful left atrial appendage exclusion by 
computed tomography angiography or transesophageal 
echocardiography imaging (Ailawadi G et al, J Thorac 
Cardiovasc Surg 2011; 142:1002-1009).  
 
SCN5A Mutations Associate With Arrhythmic Dilated 
Cardiomyopathy and Commonly Localize to the 
Voltage-Sensing Mechanism 
In this study the role of the cardiac sodium ion 
channel SCN5A in the etiology of dilated 
cardiomyopathy (DCM) was examined. To achieve this, 
DNA samples from 338 individuals among 289 DCM 
families were screened for SCN5A mutations by 
sequence analysis. The authors identified 5 missense 
SCN5A mutations representing the 1.7% of DCM 
families. Three of these mutations are novel (E446K, 
F1520L, and V1279I) and two are already known ones 
(D1275N and R222Q). In the majority of the cases the 
mutation was located to the highly conserved 
homologous S3 and S4 transmembrane segments, 
suggesting the disruption of the voltage-sensing 
mechanism of this sodium channel as the underlying 
mechanism leading to DCM. Most of the SCN5A 
mutation carriers manifested supraventricular arrhythmia 
(13/15), sick sinus syndrome (5/15) atrial fibrillation 
(9/15), ventricular tachycardia (5/15), and conduction 
disease (9/15) (McNair WP et al, J Am Coll Cardiol 
2011;57: 2160-2168.) 
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Diagnostic Accuracy of NT-proBNP ratio (BNP-R) for 
Early Diagnosis of Tachycardia-Mediated 
Cardiomyopathy: a Pilot Study 
In this single center srudy, 40 patients with 
supraventricular arrhythmia (SVT), a resting heart rate 
≥100 bpm and an impaired left ventricular ejection 
fraction <40% were selected among 387 consecutive 
patients with SVT. Successful electrical cardioversion 
was performed in all patients. NT-proBNP, NT-proBNP 
ratio (BNP-R)  calculated as a quotient of baseline NT-
proBNP/follow-up NT-proBNP and echocardiographic 
parameters were measured, and evaluated at baseline, day 
1 and weekly for 4 weeks. Cardiac catheterization was 
performed at the end of the fourth week to identify 
patients with a final diagnosis of tachycardia-mediated 
cardiomyopathy (TMC) vs major structural heart disease 
(MSHD). The most reliable variable to discriminate 
between TMC and MSHD proved to be BNP-R based on 
multivariate regression and receiver operator curve 
(ROC) analysis. The area under the ROC curve for BNP-
R to detect TMC was 0.90 (p<0.001) after 1 week and 
0.995 (p < 0.0001) after 4 weeks. At one week post-
cardioversion, a BNP-R cutoff ≥2.3 could identify TMC 
with an accuracy of 90%, sensitivity of 84% & specificity 
of 95% (Nia AM et al, Clin Res Cardiol 2011;100: 887-
896).  
 
Plasma B-type Natriuretic Peptide (BNP) Levels and 
Recurrent Arrhythmia after Successful Ablation of 
Lone Atrial Fibrillation (AF) 
The authors followed up 726 patients with lone AF 
undergoing first-time arrhythmia ablation. BNP levels 
were measured on the day of ablation with a the point-of-
care Triage Meter assay (Biosite Diagnostics, San Diego, 
CA). Older age, longer duration of AF, nonparoxysmal 
AF versus paroxysmal and larger left atrial size were 
associated with elevated BNP levels. The BNP levels 
were strongly associated with arrhythmia recurrence in 
univariate (hazard ratio for +1-log-BNP change, 2.32; 
P<0.001) and covariate- (hazard ratio for +1-log-BNP 
change, 2.13; P<0.001) adjusted Cox proportional 
hazards analysis. The exact mechanism underlying this 
correlation is not entirely elucidated. Elevated BBNP 
levels may reflect increased wall stress and/or intrinsic 
atrial disease, which increase the risk of arrhythmia 
recurrence (Hussein AA et al, Circulation 2011;123: 
2077-2082).  
 
Prevention of Atrial Fibrillation (AF) with Omega-3 
Fatty Acids: a Meta-Analysis of Randomised Trials 
In a systematic review and meta-analysis, 10 
randomized clinical trials (RCTs) and 1955 patients 
published until November 2010 in MEDLINE, Web of 
Science and Cochrane clinical trials database were 
analysed. The data showed that n-3 polyunsaturated fatty 
acids (PUFA) had no significant effect on the prevention 
of AF (OR 0.81; p=0.24) although there was significant 
heterogeneity among the studies (p=0.002, I(2)=65.0%). 
Subgroup analysis showed no significant beneficial effect 
of fish oils in any subset of population (Liu T et al, Heart 
2011;97 :1034-1340).  
 
News from the ESC Meeting 2011 
 
The ARISTOTLE trial randomized 18 201 patients 
with atrial fibrillation to apixaban (5 mg orally twice 
daily) or warfarin (target INR of 2.0 to 3.0). After a 
median follow-up of 1.8 years, results showed that 
apixaban was associated with a 21% reduction in the risk 
of stroke or systemic embolism, a 31% reduction in 
bleeding, and an 11% reduction in all-cause mortality. 
 
In the dal-VESSEL trial, patients with coronary heart 
disease or equivalents and HDL-cholesterol levels <50 
mg/dLwere randomized to dalcetrapib 600 mg or placebo 
for 36 weeks. Dalcetrapib reduced CETP activity by 50% 
and increased HDL-cholesterol levels from a mean 
baseline value of  39 mg/dL to 48 mg/dL (a 31% rise) 
while no change in LDL cholesterol levels was observed. 
No difference was noted with regard either to the primary 
efficacy end-point of brachial artery FMD at 12 weeks or 
to the safety end point of the 24-hour ambulatory blood-
pressure monitoring at four weeks. 
 
The EMPHASIS-HF trial randomized 2737 patients 
with mild heart failure and an LVEF <30% or <35%  if 
QRS >130 ms to receive eplerenone or placebo on top of 
standard therapy. The primary end-point of  CV death or 
heart failure hospitalization was significantly reduced by 
37% (18.3% vs 25.9%, p,0.001). Cardiovascular death, 
heart failure hospitalization and all cause death were also 
significantly reduced, leading to a premature halting of 
the trial after a mean follow-up of 21 months. 
 
The PRODIGY trial randomized 2013 patients 
undergoing coronary stenting due to acute coronary 
syndromes (74%) or stable angina (26%), to six or 24 
months of dual antiplatelet treatment (clopidogrel plus 
aspirin). The primary end point which was all-cause 
mortality, nonfatal MI, or stroke at two years did not 
differ between the two groups (10% in both arms). On the 
contrary, TIMI major bleeding and blood transfusion 
requirements were significantly more frequent in the 24 
month group (0.6% vs 1.6%, p=0.041, 1.3% vs 2.6%, 
p=0.041 respectively).  
